Lähettäjä: Soijuv Lähetetty: 17.2.2005 12:23
Seuraavissa tutkimuksissa on havaittu AHCC:n (Active Hexose Correlated Compound) olevan käyttökelpoista (hiirikokeet) immuunijärjestelmän vahvistamisessa ja myös ennaltaehkäisevänä lääkityksenä tiloissa joissa immuunijärjestelmän toiminta on heikentynyt.Valmisteen etuna esim. immunoglobuliiniin on mm. se että sitä voidaan antaa tablettihoitona.
J Appl Physiol. 2004 Oct;97(4):1437-44. Epub 2004 Jun 11.
Related Articles,Links
http://www.ahccpublishedresearch.com/default.htm
Active hexose correlated compound enhances the immune function of mice in the hindlimb-unloading model of spaceflight conditions.
Aviles H, Belay T, Vance M, Sun B, Sonnenfeld G.
Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, Georgia 30310-1495, USA.
Hindlimb unloading is a ground-based model that simulates some of the aspects of spaceflight conditions, including lack of load bearing on hindlimbs and a fluid shift to the head. It has been shown that treatment with active hexose correlated compound (AHCC) restores resistance to infection in mice maintained under hindlimb- unloading conditions. The present study was designed to clarify the mechanisms by which AHCC enhances resistance to infection in this model. We hypothesized that oral administration of AHCC will enhance the function of the immune system, which could lead to the increased resistance to infection observed in this model. AHCC or the excipient was orally administered to mice, and the function of the immune system was assessed in spleen and peritoneal cells isolated from those groups. The results of the present study showed that administration of AHCC for 1 wk before and throughout the second day of the hindlimb-unloading period enhanced the function of the immune system assessed by spleen cell proliferation and cytokine production in spleens and nitric oxide and cytokine production in peritoneal cells.
These findings suggest that AHCC can be used as a potent immunoenhancer, especially in cases in which the immune system is suppressed by any condition, including diseases such as human immunodeficiency virus infection and cancer.
YAKUGAKU ZASSHI, 120(8 ),715-719, 2000
Prophylactic Efficacy of a Basidiomycetes Preparation AHCC against Lethal Opportunistic Infections in Mice
Hiroko ISHIBASHI, Tatsuo IKEDA, Shigeru TANSHO, Yasuo ONO, Masatoshi YAMAZAKI, Akira SATO, Keiko YAMAOKA, Hideyo YAMAGUCHI, and Shigeru ABE
Department of Microbiology and Immunology, Department of Pharmacy, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo 173-8605, Japan, Faculty of Pharmaceutical Sciences, Teikyo University, 1091-1, Suarashi, Sagamiko- cho, Tsukui-gun, Kanagawa 199-0195, Japan, and Research Center for Medical Mycology, Teikyo University, 359, Otsuka, Hachioji-shi, Tokyo 192-0352, Japan
The prophylactic effects of a Basidiomycetes preparation, AHCC, against experimental opportunistic infections were investigated in leukopenic mice. In cyclophosphamide-induced leukopenic mice, oral or intraperitoneal administration of the AHCC at doses of 1000 or 50mg/ kg/day, respectively, for 4 consecutive days prior to Candida albicans infection significantly prolonged the survival periods of the infected mice, and decreased the viable counts of C.albicans cells recovered from their kidneys. Similarly, the oral treatment with AHCC protected mice from lethal infection with Pseudomonas aeruginosa and intraperitoneal one also protected mice from infection with methicillin-resistant Staphylococcus aureus (MRSA).
These results suggest a potential usefulness of the AHCC as a prophylactic agent for the management of patients with opportunistic infections.
Key words--Basidiomycetes preparation; AHCC; Candida albicans; Pseudomonas aeruginosa; methicillin-resistant Staphyloccocus aureus (MRSA)
IMMUUNIJÄRJESTELMÄN VAHVISTAMINEN
Valvojat: Jatta1001, Borrelioosiyhdistys, Bb
IMMUUNIJÄRJESTELMÄN VAHVISTAMINEN
Viimeksi muokannut Bb, Su Maalis 08, 2009 21:31. Yhteensä muokattu 1 kertaa.
Lähettäjä: Soijuv Lähetetty: 17.2.2005 12:54
Hei, huomasin juuri että valmiste on niitä sienirihmastovalmisteita joita Hankintatukku myy Suomessa. Valmisteen nimi on Immunomax:
Immunomax®
(Mushroom Extract Capsules)
Description
* Immunomax ® contains extract from several kinds of edible mushrooms including Shitake, Maitake etc. which are cultured in liquid medium by using advanced biotechnique.
* The main active components of Immunomax® are oligosaccharides, Active Hexose Correlated Compounds (AHCC).
* The molecular weight of AHCC is about 5000 and the oligomer of glucose in AHCC has the alpha-1,4-linkage and some hydroxy group are esterized.
* AHCC or its metabolites boost the immune system.
Usage
* AHCC was discovered to be as a biological response modifier (BRM) and to possess powerful antitumor properties when given at a higher dosage.
* Research has been conducted at Hokkaido University, Kyorin University, and Teikyo University; with clinical tests performed at hospitals in the U.S.A., Japan and China.
* AHCC works by boosting the immune system function including increasing macrophages.
* AHCC also increase NK cells, killer T-cells, and to induce cytokine production; creating a stronger immune response throughout the body.
* AHCC helps to induce levels of interferon-gamma, IL-2, and TNF-alpha etc.
* Effects on survival elongation of the tumor-bearing model in combined with anti-cancer agents.
* Decreasing effects on the side effects caused by anticancer agents.
* Inducing effects on drug-metabolism enzymes in liver.
* Protective effects on liver injury.
* Effects on inhibition of lipid peroxidation.
* In animal studies, it is demonstrated that AHCC prevent streptozotocin (STZ)-induced pancreatic injury in rats by oral administration. AHCC showed a significant activity to prevent rats from STZ-induced diabetes.
* AHCC suppressed several physiological and biochemical disorders such as hepatic injuries, cardiovascular disorders occurred by a long-term administration of EtOH.
* AHCC relieves the toxicity of antitumor agents fluorouracil (5-FU) and cyclophosphamide (CY).
Clinical effectiveness
* Recently, several clinical investigations have proved that AHCC shows several effects. AHCC is usually used as an adjuvant to cancer patients with other antitumor chemotherapeutics or as a preventive agent for the side-effects of chemical therapeutics in cancer treatment.
* In one study, AHCC was administrated for 300 progressive and end-stage cancer patients at doses of 3g/day or 6g/day, cancer disappeared completely in 25 patients and in 28 patients cancer decreased more than 50%. Table 1 shows the results of AHCC effectiveness.
* AHCC is effective on keeping good QOL (quality of life) states such as increasing appetite, feeling good, sleeping well and recovering from fatigue at terminal treatment in cancer patients.
* AHCC is a functional food effective on the hepatocellular carcinoma combined with cirrhosis with ascites.
* There was no clear change in white blood cell (WBC), hemoglobin, hematocrit and thrombocyte number after taking AHCC, even though, they were undergoing radiotherapy or chemotherapy. So this study suggests that AHCC can be used for prevention of bone marrow suppression of chemotherapy.
* Natural killer cells increased about 20% 3-6 months after taking AHCC.
* There was no clear change in the ratio of CD4/CD8 till the first 3 months. It decreased a little after 6 months.
* From the hematoimmunologiacal point of view, AHCC treatment seems to be safe and good for cancer patients.
Other actions (9th and 10th International Symposium of AHCC Research Association, 2002)
* chronic fatigue syndrome.
* hepatitis C or cirrhosis.
* chronic lymphocytic leukemia.
* breast cancer : investigation of 47 cases of breast cancer patients taking AHCC showed AHCC treatment might improve the prognosis of breast cancer patients with stage IV (p.109, 10th International Symposium of AHCC Research Association, 2002).
* AHCC intake can be as a complementary therapy of postoperative hepatocellular carcinoma patients suppressing hepatitis, preventing recurrence of hepatocellular carcinoma and prolonging survival rate (p. 116, 10th International Symposium of AHCC Research Association, 2002).
* liver cancer
* AHCC treatment improved chemotherapy induced digestive tract side effects, inhibited chemotherapy induced WBC reduction (p. 119, 2002, 10th International Symposium of AHCC Research Association, 2002).
* Allergic diseases
* In China 97 patients was followed through follow up investigation. The cancers included tongue, esophagus, gastric, stomach, colon, liver. As a result 84% cases showed effectiveness ( p. 93, 9th International Symposium of AHCC Research Association, 2001).
Dosage
For normal daily use, keeping good immunity:
1 capsule,twice daily
For therapeutical use:
4-8 capsules/time
3 times daily
Package
80 capsules /38 g
References
1. Active hexose correlated compound enhances the immune function of mice in the hindlimb-unloading model of spaceflight conditions.
Aviles H, Belay T, Vance M, Sun B, Sonnenfeld G.
J Appl Physiol. 2004 Oct;97(4):1437-44
2. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study.
Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, Imamura A, Takai S, Kawaguchi Y, Kwon AH, Kamiyama Y.
J Hepatol 2002 Jul;37(1):78-86
3. H-2 haplotype-dependent serum IL-12 production in tumor-bearing mice treated with various mycelial extracts.
Yagita A, Maruyama S, Wakasugi S, Sukegawa Y.
In Vivo 2002 Jan-Feb;16(1):49-54
4. [Prophylactic efficacy of a basidiomycetes preparation AHCC against lethal opportunistic infections in mice]
Ishibashi H, Ikeda T, Tansho S, Ono Y, Yamazaki M, Sato A, Yamaoka K, Yamaguchi H, Abe S.
Yakugaku Zasshi 2000 Aug;120(8 ):715-9
5. The use of mushroom glucans and proteoglycans in cancer treatment.
Kidd PM.
Altern Med Rev 2000 Feb;5(1):4-27
6. R. Chang
Functional properties of edible mushrooms
Nutr. Rev. 54, Pt.2, S91-93 (1996)
7. F. Liu et al.
Free radical scavenging activities of mushroom polysaccharide extract
Life Sci. 60, 763-771 (1997)
(References searched and cited from PubMed at http://www.ncbi.nlm.nih.gov/PubMed/)
This site edited and maintained by Yu Heci
Updated February 14, 2005
Copyright © 1998-2005
Hankintatukku Natural Health Products Co.
Museokatu 13 B, FIN-00100, Helsinki, FINLAND
Hei, huomasin juuri että valmiste on niitä sienirihmastovalmisteita joita Hankintatukku myy Suomessa. Valmisteen nimi on Immunomax:
Immunomax®
(Mushroom Extract Capsules)
Description
* Immunomax ® contains extract from several kinds of edible mushrooms including Shitake, Maitake etc. which are cultured in liquid medium by using advanced biotechnique.
* The main active components of Immunomax® are oligosaccharides, Active Hexose Correlated Compounds (AHCC).
* The molecular weight of AHCC is about 5000 and the oligomer of glucose in AHCC has the alpha-1,4-linkage and some hydroxy group are esterized.
* AHCC or its metabolites boost the immune system.
Usage
* AHCC was discovered to be as a biological response modifier (BRM) and to possess powerful antitumor properties when given at a higher dosage.
* Research has been conducted at Hokkaido University, Kyorin University, and Teikyo University; with clinical tests performed at hospitals in the U.S.A., Japan and China.
* AHCC works by boosting the immune system function including increasing macrophages.
* AHCC also increase NK cells, killer T-cells, and to induce cytokine production; creating a stronger immune response throughout the body.
* AHCC helps to induce levels of interferon-gamma, IL-2, and TNF-alpha etc.
* Effects on survival elongation of the tumor-bearing model in combined with anti-cancer agents.
* Decreasing effects on the side effects caused by anticancer agents.
* Inducing effects on drug-metabolism enzymes in liver.
* Protective effects on liver injury.
* Effects on inhibition of lipid peroxidation.
* In animal studies, it is demonstrated that AHCC prevent streptozotocin (STZ)-induced pancreatic injury in rats by oral administration. AHCC showed a significant activity to prevent rats from STZ-induced diabetes.
* AHCC suppressed several physiological and biochemical disorders such as hepatic injuries, cardiovascular disorders occurred by a long-term administration of EtOH.
* AHCC relieves the toxicity of antitumor agents fluorouracil (5-FU) and cyclophosphamide (CY).
Clinical effectiveness
* Recently, several clinical investigations have proved that AHCC shows several effects. AHCC is usually used as an adjuvant to cancer patients with other antitumor chemotherapeutics or as a preventive agent for the side-effects of chemical therapeutics in cancer treatment.
* In one study, AHCC was administrated for 300 progressive and end-stage cancer patients at doses of 3g/day or 6g/day, cancer disappeared completely in 25 patients and in 28 patients cancer decreased more than 50%. Table 1 shows the results of AHCC effectiveness.
* AHCC is effective on keeping good QOL (quality of life) states such as increasing appetite, feeling good, sleeping well and recovering from fatigue at terminal treatment in cancer patients.
* AHCC is a functional food effective on the hepatocellular carcinoma combined with cirrhosis with ascites.
- Table 1. Cancer Cases Change in Their Cancer Size after Using AHCC
Cancers Completely Disappear Decreasing size over 50% Total Cases
Cases
Tongue - 1 1
Lung 1 5 6
Hepatocellular carcinoma 2 4 6
Breast 4 6 10
Gastric 5 - 5
Colon 3 2 5
Esophagus 2 - 2
Testicular Carcinoma 3 - 3
Ovarian 3 2 5
Prostatic Cancer 1 5 6
Renal Cancer - 2 2
Thyloid carcinoma 1 1 2
Total cases 25 28 53
* There was no clear change in white blood cell (WBC), hemoglobin, hematocrit and thrombocyte number after taking AHCC, even though, they were undergoing radiotherapy or chemotherapy. So this study suggests that AHCC can be used for prevention of bone marrow suppression of chemotherapy.
* Natural killer cells increased about 20% 3-6 months after taking AHCC.
* There was no clear change in the ratio of CD4/CD8 till the first 3 months. It decreased a little after 6 months.
* From the hematoimmunologiacal point of view, AHCC treatment seems to be safe and good for cancer patients.
Other actions (9th and 10th International Symposium of AHCC Research Association, 2002)
* chronic fatigue syndrome.
* hepatitis C or cirrhosis.
* chronic lymphocytic leukemia.
* breast cancer : investigation of 47 cases of breast cancer patients taking AHCC showed AHCC treatment might improve the prognosis of breast cancer patients with stage IV (p.109, 10th International Symposium of AHCC Research Association, 2002).
* AHCC intake can be as a complementary therapy of postoperative hepatocellular carcinoma patients suppressing hepatitis, preventing recurrence of hepatocellular carcinoma and prolonging survival rate (p. 116, 10th International Symposium of AHCC Research Association, 2002).
* liver cancer
* AHCC treatment improved chemotherapy induced digestive tract side effects, inhibited chemotherapy induced WBC reduction (p. 119, 2002, 10th International Symposium of AHCC Research Association, 2002).
* Allergic diseases
* In China 97 patients was followed through follow up investigation. The cancers included tongue, esophagus, gastric, stomach, colon, liver. As a result 84% cases showed effectiveness ( p. 93, 9th International Symposium of AHCC Research Association, 2001).
Dosage
For normal daily use, keeping good immunity:
1 capsule,twice daily
For therapeutical use:
4-8 capsules/time
3 times daily
Package
80 capsules /38 g
References
1. Active hexose correlated compound enhances the immune function of mice in the hindlimb-unloading model of spaceflight conditions.
Aviles H, Belay T, Vance M, Sun B, Sonnenfeld G.
J Appl Physiol. 2004 Oct;97(4):1437-44
2. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study.
Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, Imamura A, Takai S, Kawaguchi Y, Kwon AH, Kamiyama Y.
J Hepatol 2002 Jul;37(1):78-86
3. H-2 haplotype-dependent serum IL-12 production in tumor-bearing mice treated with various mycelial extracts.
Yagita A, Maruyama S, Wakasugi S, Sukegawa Y.
In Vivo 2002 Jan-Feb;16(1):49-54
4. [Prophylactic efficacy of a basidiomycetes preparation AHCC against lethal opportunistic infections in mice]
Ishibashi H, Ikeda T, Tansho S, Ono Y, Yamazaki M, Sato A, Yamaoka K, Yamaguchi H, Abe S.
Yakugaku Zasshi 2000 Aug;120(8 ):715-9
5. The use of mushroom glucans and proteoglycans in cancer treatment.
Kidd PM.
Altern Med Rev 2000 Feb;5(1):4-27
6. R. Chang
Functional properties of edible mushrooms
Nutr. Rev. 54, Pt.2, S91-93 (1996)
7. F. Liu et al.
Free radical scavenging activities of mushroom polysaccharide extract
Life Sci. 60, 763-771 (1997)
(References searched and cited from PubMed at http://www.ncbi.nlm.nih.gov/PubMed/)
This site edited and maintained by Yu Heci
Updated February 14, 2005
Copyright © 1998-2005
Hankintatukku Natural Health Products Co.
Museokatu 13 B, FIN-00100, Helsinki, FINLAND